Quality of anticoagulation and treatment satisfaction in patients with non-valvular atrial fibrillation treated with vitamin K antagonist

Result from the Korean atrial fibrillation investigation II

Seil Oh, June Soo Kim, Yong Seog Oh, Dong Gu Shin, Hui Nam Pak, Gyo Seung Hwang, Kee Joon Choi, Jin Bae Kim, Man Young Lee, Hyung Wook Park, Dae Kyeong Kim, Eun Sun Jin, Jaeseok Park, Il Young Oh, Dae Hee Shin, Hyoung Seob Park, Jun Hyung Kim, Nam Ho Kim, Min Soo Ahn, Bo Jeong Seo & 4 others Young Joo Kim, Seongsik Kang, Juneyoung Lee, Young Hoon Kim

Research output: Contribution to journalArticle

Abstract

Background: Vitamin K antagonist (VKA) to prevent thromboembolism in non-valvular atrial fibrillation (NVAF) patients has limitations such as drug interaction. This study investigated the clinical characteristics of Korean patients treated with VKA for stroke prevention and assessed quality of VKA therapy and treatment satisfaction. Methods: We conducted a multicenter, prospective, non-interventional study. Patients with CHADS2 ≥ 1 and treated with VKA (started within the last 3 months) were enrolled from April 2013 to March 2014. Demographic and clinical features including risk factors of stroke and VKA treatment information was collected at baseline. Treatment patterns and international normalized ratio (INR) level were evaluated during follow-up. Time in therapeutic range (TTR) > 60% indicated well-controlled INR. Treatment satisfaction on the VKA use was measured by Treatment Satisfaction Questionnaire for Medication (TSQM) after 3 months of follow-up. Results: A total of 877 patients (age, 67; male, 60%) were enrolled and followed up for one year. More than half of patients (56%) had CHADS2 ≥ 2 and 83.6% had CHA2DS2-VASc ≥ 2. A total of 852 patients had one or more INR measurement during their follow-up period. Among those patients, 25.5% discontinued VKA treatment during follow-up. Of all patients, 626 patients (73%) had poor-controlled INR (TTR < 60%) measure. Patients' treatment satisfaction measured with TSQM was 55.6 in global satisfaction domain. Conclusion: INR was poorly controlled in Korean NVAF patients treated with VKA. VKA users also showed low treatment satisfaction.

Original languageEnglish
Article numbere323
JournalJournal of Korean Medical Science
Volume33
Issue number49
DOIs
Publication statusPublished - 2018 Dec 1

Fingerprint

Vitamin K
Patient Satisfaction
Atrial Fibrillation
International Normalized Ratio
Therapeutics
Stroke
Thromboembolism
Drug Interactions
Demography

Keywords

  • Anticoagulation
  • Atrial fibrillation
  • INR control
  • Satisfaction
  • Vitamin K antagonist

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Quality of anticoagulation and treatment satisfaction in patients with non-valvular atrial fibrillation treated with vitamin K antagonist : Result from the Korean atrial fibrillation investigation II. / Oh, Seil; Kim, June Soo; Oh, Yong Seog; Shin, Dong Gu; Pak, Hui Nam; Hwang, Gyo Seung; Choi, Kee Joon; Kim, Jin Bae; Lee, Man Young; Park, Hyung Wook; Kim, Dae Kyeong; Jin, Eun Sun; Park, Jaeseok; Oh, Il Young; Shin, Dae Hee; Park, Hyoung Seob; Kim, Jun Hyung; Kim, Nam Ho; Ahn, Min Soo; Seo, Bo Jeong; Kim, Young Joo; Kang, Seongsik; Lee, Juneyoung; Kim, Young Hoon.

In: Journal of Korean Medical Science, Vol. 33, No. 49, e323, 01.12.2018.

Research output: Contribution to journalArticle

Oh, S, Kim, JS, Oh, YS, Shin, DG, Pak, HN, Hwang, GS, Choi, KJ, Kim, JB, Lee, MY, Park, HW, Kim, DK, Jin, ES, Park, J, Oh, IY, Shin, DH, Park, HS, Kim, JH, Kim, NH, Ahn, MS, Seo, BJ, Kim, YJ, Kang, S, Lee, J & Kim, YH 2018, 'Quality of anticoagulation and treatment satisfaction in patients with non-valvular atrial fibrillation treated with vitamin K antagonist: Result from the Korean atrial fibrillation investigation II', Journal of Korean Medical Science, vol. 33, no. 49, e323. https://doi.org/10.3346/jkms.2018.33.e323
Oh, Seil ; Kim, June Soo ; Oh, Yong Seog ; Shin, Dong Gu ; Pak, Hui Nam ; Hwang, Gyo Seung ; Choi, Kee Joon ; Kim, Jin Bae ; Lee, Man Young ; Park, Hyung Wook ; Kim, Dae Kyeong ; Jin, Eun Sun ; Park, Jaeseok ; Oh, Il Young ; Shin, Dae Hee ; Park, Hyoung Seob ; Kim, Jun Hyung ; Kim, Nam Ho ; Ahn, Min Soo ; Seo, Bo Jeong ; Kim, Young Joo ; Kang, Seongsik ; Lee, Juneyoung ; Kim, Young Hoon. / Quality of anticoagulation and treatment satisfaction in patients with non-valvular atrial fibrillation treated with vitamin K antagonist : Result from the Korean atrial fibrillation investigation II. In: Journal of Korean Medical Science. 2018 ; Vol. 33, No. 49.
@article{c62f8ccae2ff41f989ab2827d2f7725e,
title = "Quality of anticoagulation and treatment satisfaction in patients with non-valvular atrial fibrillation treated with vitamin K antagonist: Result from the Korean atrial fibrillation investigation II",
abstract = "Background: Vitamin K antagonist (VKA) to prevent thromboembolism in non-valvular atrial fibrillation (NVAF) patients has limitations such as drug interaction. This study investigated the clinical characteristics of Korean patients treated with VKA for stroke prevention and assessed quality of VKA therapy and treatment satisfaction. Methods: We conducted a multicenter, prospective, non-interventional study. Patients with CHADS2 ≥ 1 and treated with VKA (started within the last 3 months) were enrolled from April 2013 to March 2014. Demographic and clinical features including risk factors of stroke and VKA treatment information was collected at baseline. Treatment patterns and international normalized ratio (INR) level were evaluated during follow-up. Time in therapeutic range (TTR) > 60{\%} indicated well-controlled INR. Treatment satisfaction on the VKA use was measured by Treatment Satisfaction Questionnaire for Medication (TSQM) after 3 months of follow-up. Results: A total of 877 patients (age, 67; male, 60{\%}) were enrolled and followed up for one year. More than half of patients (56{\%}) had CHADS2 ≥ 2 and 83.6{\%} had CHA2DS2-VASc ≥ 2. A total of 852 patients had one or more INR measurement during their follow-up period. Among those patients, 25.5{\%} discontinued VKA treatment during follow-up. Of all patients, 626 patients (73{\%}) had poor-controlled INR (TTR < 60{\%}) measure. Patients' treatment satisfaction measured with TSQM was 55.6 in global satisfaction domain. Conclusion: INR was poorly controlled in Korean NVAF patients treated with VKA. VKA users also showed low treatment satisfaction.",
keywords = "Anticoagulation, Atrial fibrillation, INR control, Satisfaction, Vitamin K antagonist",
author = "Seil Oh and Kim, {June Soo} and Oh, {Yong Seog} and Shin, {Dong Gu} and Pak, {Hui Nam} and Hwang, {Gyo Seung} and Choi, {Kee Joon} and Kim, {Jin Bae} and Lee, {Man Young} and Park, {Hyung Wook} and Kim, {Dae Kyeong} and Jin, {Eun Sun} and Jaeseok Park and Oh, {Il Young} and Shin, {Dae Hee} and Park, {Hyoung Seob} and Kim, {Jun Hyung} and Kim, {Nam Ho} and Ahn, {Min Soo} and Seo, {Bo Jeong} and Kim, {Young Joo} and Seongsik Kang and Juneyoung Lee and Kim, {Young Hoon}",
year = "2018",
month = "12",
day = "1",
doi = "10.3346/jkms.2018.33.e323",
language = "English",
volume = "33",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "49",

}

TY - JOUR

T1 - Quality of anticoagulation and treatment satisfaction in patients with non-valvular atrial fibrillation treated with vitamin K antagonist

T2 - Result from the Korean atrial fibrillation investigation II

AU - Oh, Seil

AU - Kim, June Soo

AU - Oh, Yong Seog

AU - Shin, Dong Gu

AU - Pak, Hui Nam

AU - Hwang, Gyo Seung

AU - Choi, Kee Joon

AU - Kim, Jin Bae

AU - Lee, Man Young

AU - Park, Hyung Wook

AU - Kim, Dae Kyeong

AU - Jin, Eun Sun

AU - Park, Jaeseok

AU - Oh, Il Young

AU - Shin, Dae Hee

AU - Park, Hyoung Seob

AU - Kim, Jun Hyung

AU - Kim, Nam Ho

AU - Ahn, Min Soo

AU - Seo, Bo Jeong

AU - Kim, Young Joo

AU - Kang, Seongsik

AU - Lee, Juneyoung

AU - Kim, Young Hoon

PY - 2018/12/1

Y1 - 2018/12/1

N2 - Background: Vitamin K antagonist (VKA) to prevent thromboembolism in non-valvular atrial fibrillation (NVAF) patients has limitations such as drug interaction. This study investigated the clinical characteristics of Korean patients treated with VKA for stroke prevention and assessed quality of VKA therapy and treatment satisfaction. Methods: We conducted a multicenter, prospective, non-interventional study. Patients with CHADS2 ≥ 1 and treated with VKA (started within the last 3 months) were enrolled from April 2013 to March 2014. Demographic and clinical features including risk factors of stroke and VKA treatment information was collected at baseline. Treatment patterns and international normalized ratio (INR) level were evaluated during follow-up. Time in therapeutic range (TTR) > 60% indicated well-controlled INR. Treatment satisfaction on the VKA use was measured by Treatment Satisfaction Questionnaire for Medication (TSQM) after 3 months of follow-up. Results: A total of 877 patients (age, 67; male, 60%) were enrolled and followed up for one year. More than half of patients (56%) had CHADS2 ≥ 2 and 83.6% had CHA2DS2-VASc ≥ 2. A total of 852 patients had one or more INR measurement during their follow-up period. Among those patients, 25.5% discontinued VKA treatment during follow-up. Of all patients, 626 patients (73%) had poor-controlled INR (TTR < 60%) measure. Patients' treatment satisfaction measured with TSQM was 55.6 in global satisfaction domain. Conclusion: INR was poorly controlled in Korean NVAF patients treated with VKA. VKA users also showed low treatment satisfaction.

AB - Background: Vitamin K antagonist (VKA) to prevent thromboembolism in non-valvular atrial fibrillation (NVAF) patients has limitations such as drug interaction. This study investigated the clinical characteristics of Korean patients treated with VKA for stroke prevention and assessed quality of VKA therapy and treatment satisfaction. Methods: We conducted a multicenter, prospective, non-interventional study. Patients with CHADS2 ≥ 1 and treated with VKA (started within the last 3 months) were enrolled from April 2013 to March 2014. Demographic and clinical features including risk factors of stroke and VKA treatment information was collected at baseline. Treatment patterns and international normalized ratio (INR) level were evaluated during follow-up. Time in therapeutic range (TTR) > 60% indicated well-controlled INR. Treatment satisfaction on the VKA use was measured by Treatment Satisfaction Questionnaire for Medication (TSQM) after 3 months of follow-up. Results: A total of 877 patients (age, 67; male, 60%) were enrolled and followed up for one year. More than half of patients (56%) had CHADS2 ≥ 2 and 83.6% had CHA2DS2-VASc ≥ 2. A total of 852 patients had one or more INR measurement during their follow-up period. Among those patients, 25.5% discontinued VKA treatment during follow-up. Of all patients, 626 patients (73%) had poor-controlled INR (TTR < 60%) measure. Patients' treatment satisfaction measured with TSQM was 55.6 in global satisfaction domain. Conclusion: INR was poorly controlled in Korean NVAF patients treated with VKA. VKA users also showed low treatment satisfaction.

KW - Anticoagulation

KW - Atrial fibrillation

KW - INR control

KW - Satisfaction

KW - Vitamin K antagonist

UR - http://www.scopus.com/inward/record.url?scp=85057627506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057627506&partnerID=8YFLogxK

U2 - 10.3346/jkms.2018.33.e323

DO - 10.3346/jkms.2018.33.e323

M3 - Article

VL - 33

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 49

M1 - e323

ER -